Correlation Between Krystal Biotech and Hepion Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Krystal Biotech and Hepion Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Krystal Biotech and Hepion Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Krystal Biotech and Hepion Pharmaceuticals, you can compare the effects of market volatilities on Krystal Biotech and Hepion Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Krystal Biotech with a short position of Hepion Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Krystal Biotech and Hepion Pharmaceuticals.

Diversification Opportunities for Krystal Biotech and Hepion Pharmaceuticals

0.44

Correlation Coefficient

Krystal Biotech  Hepion Pharmaceuticals

Very weak diversification

The 3 months correlation between Krystal and Hepion is 0.44. Overlapping area represents the amount of risk that can be diversified away by holding Krystal Biotech and Hepion Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Hepion Pharmaceuticals and Krystal Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Krystal Biotech are associated (or correlated) with Hepion Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Hepion Pharmaceuticals has no effect on the direction of Krystal Biotech i.e., Krystal Biotech and Hepion Pharmaceuticals go up and down completely randomly.

Pair Corralation between Krystal Biotech and Hepion Pharmaceuticals

Given the investment horizon of 90 days Krystal Biotech is expected to generate 0.44 times more return on investment than Hepion Pharmaceuticals. However, Krystal Biotech is 2.27 times less risky than Hepion Pharmaceuticals. It trades about 0.02 of its potential returns per unit of risk. Hepion Pharmaceuticals is currently generating about -0.05 per unit of risk. If you would invest  19,512  in Krystal Biotech on August 30, 2024 and sell it today you would earn a total of  179.00  from holding Krystal Biotech or generate 0.92% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	98.44%
Values	Daily Returns

Krystal Biotech  vs.  Hepion Pharmaceuticals

Krystal Biotech

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Krystal Biotech are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable basic indicators, Krystal Biotech is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Hepion Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Hepion Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Krystal Biotech and Hepion Pharmaceuticals

The main advantage of trading using opposite Krystal Biotech and Hepion Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Krystal Biotech position performs unexpectedly, Hepion Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hepion Pharmaceuticals will offset losses from the drop in Hepion Pharmaceuticals' long position.

The idea behind Krystal Biotech and Hepion Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.